Curanex's R&D Surge Drives Losses, IPO Boosts Cash to $5.8M

TL;DR

**Curanex is burning cash on R&D post-IPO, but their fresh $15M war chest means they're all-in on pipeline development, making it a speculative but funded bet.**

AI Summary

Curanex Pharmaceuticals Inc. (CURX) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $1,151,988, a substantial rise from $215,567 in the same period of 2024. This increase was primarily driven by a surge in Research & Development (R&D) expenses, which totaled $679,574 for the nine months ended September 30, 2025, compared to zero in the prior year, reflecting intensified preclinical development activities for inflammatory disease treatments. General & administrative expenses also rose to $466,863 from $217,696. Despite the increased losses, the company's financial position was significantly bolstered by its Initial Public Offering (IPO) on August 27, 2025, which generated net proceeds of approximately $13.24 million, and an additional $2.07 million from the underwriters' over-allotment option exercised in September 2025. As a result, cash and cash equivalents dramatically increased to $5,830,537 as of September 30, 2025, from $148,891 at December 31, 2024, alleviating prior going concern doubts. Total assets grew to $14,478,157 from $517,935, while total liabilities increased to $185,955 from $14,575.

Why It Matters

This filing is critical for investors as it reveals Curanex's post-IPO financial health and strategic direction. The substantial increase in R&D spending, particularly for IND-enabling studies in inflammatory diseases, signals aggressive pipeline development, which could be a long-term value driver but also a short-term drag on profitability. The successful IPO and over-allotment exercise, bringing in over $15 million, significantly de-risks the company's liquidity, addressing prior going concern issues and providing capital for its ambitious drug development programs. In a competitive pharmaceutical landscape, this cash infusion is vital for Curanex to advance its botanical drug candidates and potentially challenge established players in the inflammatory disease market, impacting future market share and patient treatment options.

Risk Assessment

Risk Level: medium — The company reported a net loss of $1,151,988 for the nine months ended September 30, 2025, and has an accumulated deficit of $1,774,437. While the successful IPO provided $15.3 million in net proceeds and alleviated going concern doubts, the significant R&D expenditures of $679,574 for the nine months ended September 30, 2025, indicate continued cash burn without immediate revenue, posing a medium-term operational risk.

Analyst Insight

Investors should monitor Curanex's R&D progress closely, specifically the advancement of its IND-enabling studies for ulcerative colitis, atopic dermatitis, rheumatoid arthritis, gouty arthritis, and diabetic foot. The substantial cash reserves from the IPO provide a runway, but future clinical trial results and potential regulatory milestones will be crucial for long-term valuation. Consider this a high-growth, high-risk play contingent on successful drug development.

Financial Highlights

debt To Equity

0.01

revenue

N/A

operating Margin

N/A

total Assets

$14,478,157

total Debt

$185,955

net Income

-$1,151,988

eps

-$0.05

gross Margin

N/A

cash Position

$5,830,537

revenue Growth

N/A

Key Numbers

• $1,151,988 — Net Loss (for the nine months ended September 30, 2025, up from $215,567 in 2024)
• $679,574 — Research & Development Expense (for the nine months ended September 30, 2025, up from $0 in 2024)
• $13.24 million — Net Proceeds from IPO (received in August 2025)
• $2.07 million — Net Proceeds from Over-Allotment Option (received in September 2025)
• $5,830,537 — Cash and Cash Equivalents (as of September 30, 2025, up from $148,891 at December 31, 2024)
• $14,478,157 — Total Assets (as of September 30, 2025, up from $517,935 at December 31, 2024)
• 28,340,812 — Common Shares Outstanding (as of November 14, 2025)
• $4.00 — IPO Price Per Share (public offering price on August 27, 2025)

Key Players & Entities

• Curanex Pharmaceuticals Inc. (company) — registrant
• Nasdaq Capital Market (regulator) — exchange where CURX trades
• SEC (regulator) — Securities and Exchange Commission
• Nevada (regulator) — state of incorporation
• New York (regulator) — former state of incorporation
• Durand Damiel Health Inc. (company) — original name of the company
• FDA (regulator) — Food and Drug Administration
• FDIC (regulator) — Federal Deposit Insurance Corporation

FAQ

Risk Factors

• Increased Net Loss [medium — financial]: The company reported a net loss of $1,151,988 for the nine months ended September 30, 2025, a significant increase from $215,567 in the same period of 2024. This widening loss is primarily due to a substantial rise in R&D expenses.
• Surge in R&D Expenses [medium — financial]: Research and Development expenses increased from $0 in the nine months ended September 30, 2024, to $679,574 in the same period of 2025. This reflects intensified preclinical development activities, which are crucial but costly for a pharmaceutical company.
• Rising General & Administrative Costs [low — financial]: General & administrative expenses rose to $466,863 for the nine months ended September 30, 2025, from $217,696 in the prior year. This increase may be related to scaling operations post-IPO.
• Dependence on IPO Proceeds [high — financial]: The company's improved cash position is heavily reliant on the $13.24 million from its IPO and $2.07 million from the over-allotment option. Future funding will be critical to sustain operations and development.
• Preclinical Development Stage [high — operational]: Curanex is focused on inflammatory disease treatments in preclinical development. This stage is inherently risky, with high failure rates and long development timelines before potential commercialization.

Industry Context

Curanex Pharmaceuticals operates in the highly competitive and capital-intensive biotechnology sector, focusing on the development of treatments for inflammatory diseases. This industry is characterized by long development cycles, significant R&D investment, and high regulatory hurdles. Success hinges on innovation, clinical trial outcomes, and securing substantial funding to navigate the path from preclinical research to market approval.

Regulatory Implications

As a pharmaceutical company, Curanex is subject to stringent regulations from bodies like the FDA. The company must adhere to rigorous standards for drug development, clinical trials, and manufacturing. Failure to comply with these regulations or unexpected outcomes in clinical trials can lead to significant delays, increased costs, or outright failure of drug candidates.

What Investors Should Do

1. Monitor R&D progress and clinical trial milestones.
2. Assess cash burn rate and future funding needs.
3. Evaluate the competitive landscape for inflammatory disease treatments.

Key Dates

• 2025-08-27: Initial Public Offering (IPO) — Raised approximately $13.24 million, significantly bolstering the company's cash reserves and alleviating prior going concern doubts.
• 2025-09-30: End of Nine-Month Period — Reported increased net loss of $1,151,988, driven by R&D investments, but also a substantial increase in cash and total assets due to the IPO.
• 2025-09: Underwriters' Over-Allotment Option Exercised — Provided an additional $2.07 million in funding, further strengthening the company's financial position.

Glossary

Accumulated deficit

The total net losses of a company since its inception that have not been offset by net income. (Shows the cumulative losses incurred by Curanex, which increased significantly in the nine months ended September 30, 2025, to $1,774,437.)

Additional paid-in capital

The amount of money a company receives from selling stock above its par value. (This account saw a substantial increase, reaching $16,063,705 as of September 30, 2025, primarily due to the IPO proceeds.)

Right-of-Use Asset

An asset representing a lessee's right to use a leased asset over the lease term, recognized under ASC 842. (Appeared on the balance sheet as of September 30, 2025, with a value of $60,398, indicating the adoption of lease accounting standards for new leases.)

Preclinical development

The stage of drug development that occurs before human testing, involving laboratory and animal studies to assess safety and efficacy. (This is the primary focus of Curanex's R&D spending, indicating the company is in the early, high-risk phase of drug discovery.)

Year-Over-Year Comparison

Compared to the prior year's comparable period (nine months ended September 30, 2024), Curanex Pharmaceuticals Inc. has experienced a dramatic increase in its net loss, rising from $215,567 to $1,151,988. This is largely attributable to the initiation of significant Research & Development activities, which were $0 in the prior period and $679,574 in the current period, alongside increased General & Administrative expenses. Despite the widening loss, the company's financial position has been vastly improved by its recent IPO, leading to a substantial increase in cash and total assets, while total liabilities remain relatively low.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share CURX The Nasdaq Capital M

Filing Documents

• form10-q.htm (10-Q) — 597KB
• ex31-1.htm (EX-31.1) — 10KB
• ex31-2.htm (EX-31.2) — 9KB
• ex32-1.htm (EX-32.1) — 4KB
• ex32-2.htm (EX-32.2) — 4KB
• 0001493152-25-023710.txt ( ) — 3159KB
• curx-20250930.xsd (EX-101.SCH) — 22KB
• curx-20250930_cal.xml (EX-101.CAL) — 32KB
• curx-20250930_def.xml (EX-101.DEF) — 51KB
• curx-20250930_lab.xml (EX-101.LAB) — 224KB
• curx-20250930_pre.xml (EX-101.PRE) — 171KB
• form10-q_htm.xml (XML) — 466KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 4 Item 1. Unaudited Financial Statements. 4 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations. 20 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk. 25 Item 4.

Controls and Procedures

Controls and Procedures. 26

– OTHER INFORMATION

PART II – OTHER INFORMATION 26 Item 1. Legal Proceedings. 26 Item 1A. Risk Factors. 26 Item 2. Unregistered Sales of Equity Securities. 26 Item 3. Defaults Upon Senior Securities. 27 Item 4. Mine Safety Disclosures. 27 Item 5. Other Information. 27 Item 6. Exhibits. 27

SIGNATURES

SIGNATURES 28 2 FORWARD-LOOKING You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our financial This Quarterly Report contains forward-looking statements. Forward-looking statements are based upon our current assumptions, expectations and beliefs concerning future developments and their potential effect on our business. In some cases, you can identify forward-looking "expect," "intend," "plan," "anticipate," "believe," "approximately," "estimate," "predict," "project," "potential," "continue," "ongoing," or the negative of these terms or other comparable terminology, although the absence of these words does not necessarily mean that a our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by any forward-looking statements. We cannot predict all of the risks and uncertainties. Accordingly, such information should not be regarded as representations that the results or conditions described in such statements or that our objectives and plans will be achieved and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements. These forward-looking statements include information concerning possible or assumed future results of our operations, including statements about our business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future acquisitions, future cash needs, future operations, business plans and future financial results, o

Notes to Financial Statements

Notes to Financial Statements 10 5 CURANEX PHARMACEUTICALS INC BALANCE SHEETS As of September 30, 2025 As of December 31, 2024 (unaudited) ASSETS Current assets Cash $ 5,830,537 $ 148,891 Prepaid Expenses 8,587,222 1,179 Other Current Assets - 367,865 Total current assets 14,417,759 517,935 Right-of-Use Asset 60,398 - TOTAL ASSETS 14,478,157 517,935 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accrued expenses 10,316 9,575 Accounts payable 114,489 5,000 Lease Liability, current 61,150 - Total current liabilities 185,955 14,575 TOTAL LIABILITIES 185,955 14,575 Shareholders' equity Common stock, 475,000,000 shares authorized; $ 0.0001 par value; 28,340,812 shares issued and outstanding as of September 30, 2025, and 24,000,000 December 31, 2024 2,834 2,400 Preferred stock, 25,000,000 shares authorized; $ 0.0001 par value; 1,000,000 shares issued and outstanding as of September 30, 2025, and December 31, 2024 100 100 Common stock to be issued - 200,000 Additional paid-in capital 16,063,705 923,309 Accumulated deficit ( 1,774,437 ) ( 622,449 ) TOTAL SHAREHOLDERS' EQUITY 14,292,202 503,360 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 14,478,157 $ 517,935 The accompanying notes are an integral part of these unaudited financial statements. 6 CURANEX PHARMACEUTICALS INC OF OPERATIONS (unaudited) For the Three Months Ended September 30, For the Nine Months Ended September 30, 2025 2024 2025 2024 Operating expenses: General & administrative 273,853 93,295 466,863 217,696 Research & Development 677,474 - 679,574 - Total operating expenses 951,327 93,295 1,146,437 217,696 Loss from operations ( 951,327 ) ( 93,295 ) ( 1,146,437 ) ( 217,696 ) Interest Expense ( 4,090 ) - ( 8,537 ) - Other income 1,358 2,129 2,986 2,129 Net Loss $ ( 954,059 ) $ ( 91,166 ) $ ( 1,151,988 ) $ ( 215,567 ) Net loss per c

View Full Filing

View this 10-Q filing on SEC EDGAR